New pyridobenzodiazepine derivatives: Modifications of the basic side chain differentially modulate binding to dopamine (D-4.2, D-2L) and serotonin (5-HT2A) receptors
[en] A series of new pyridobenzodiazepines with variation of the basic side chain were synthesized and evaluated for their binding to D-4.2, D-2L, and 5-HT2A receptors in comparison with clozapine, haloperidol, and two parent compounds previously described, 8-chloro-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1,4]benzodiazepine (8) and 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1,4]benzodiazepine (9). In the piperazine series, replacing the N-methyl group by a N-phenyl moiety (15-17, 30-32) provided a dramatic decrease of affinity for all receptors (K-i > 1000 nM). A N-cyclohexyl group (20, 35) restored some affinity. Compounds with a N-benzyl (18, 33) or N-phenethyl side chain (19, 34) had significant affinities at D-4.2 and 5-HT2A receptors. Homologation of the piperazine nucleus (29, 44) led to a significant decrease of the affinity at all receptors investigated. In the 4-aminopiperidine series, N-methyl derivatives (21, 36) possessed less affinity in comparison with the N-metbylpiperazine analogues (8, 9) while the N-benzyl congeners (22, 37) showed similar affinities. The rigidification of piperidine nucleus as obtained in azabicyclo [3.2.1] octane derivatives (23, 38) involved a slight reduction of the affinity at D-4.2 and 5-HT2A receptors while the affinity at D-2L receptors was dramatically increased. The introduction of N-substituted aminoalkylamines to replace N-methylpiperazine generally led to a significant decrease in the affinity for D-4.2 receptors but some of these molecules (24, 25, 41) presented a significant 5-HT2A binding affinity. The presence of a more flexible side chain induced an increased conformational freedom. Consequently, the preferential position of the distal nitrogen or its basicity in piperazine derivatives was greatly modified. 19 with a high D-4.2 and 5-HT2A affinity (K-i = 40 and 103 nM, respectively) did not induce cataleptic phenomenon in the paw test in rats but significantly reduced the immobility time in Porsolt's test in mice suggesting antidepressant properties.
Disciplines :
Chemistry Pharmacy, pharmacology & toxicology
Author, co-author :
Liégeois, Jean-François ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Eyrolles, L.
Ellenbroek, B. A.
Lejeune, Corinne ; Université de Liège - ULiège > Département des sciences et gestion de l'environnement > Département des sciences et gestion de l'environnement
Carato, P.
Bruhwyler, J.
Geczy, J.
Damas, Jacques ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Delarge, J.
Language :
English
Title :
New pyridobenzodiazepine derivatives: Modifications of the basic side chain differentially modulate binding to dopamine (D-4.2, D-2L) and serotonin (5-HT2A) receptors
Publication date :
07 November 2002
Journal title :
Journal of Medicinal Chemistry
ISSN :
0022-2623
eISSN :
1520-4804
Publisher :
Amer Chemical Soc, Washington, United States - Washington
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Love, R. C.; Nelson, M. W. Pharmacology and clinical experience with risperidone. Exp. Opin. Pharmacother. 2000, 1, 1441-1453.
Brown, L. A.; Levin, G. M. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. Pharmacotherapy 1998, 18, 69-83.
Kane, J. M. Sertindole: A review of clinical efficacy. Int. Clin. Psychopharmacol. 1998, 13, S59-S63.
Bhana, N.; Foster, R. H.; Olney, R.; Plosker, G. L. Olanzapine. An updated review of its use in the management of schizophrenia. Drugs 2001, 61, 111-161.
Fulton, B.; Goa, K. L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997, 53, 281-298.
Goldstein, J. M. Quetiapine fumarate (Seroquel): A new atypical antipsychotic. Drugs Today 1999, 35, 193-210.
Kasper, S.; Müller-Spahn, F. Review of quetiapine and its clinical applications in schizophrenia. Exp. Opin. Pharmacother. 2000, 1, 783-801.
Tandon, R.; Harrigan, E.; Zorn, S. H. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential. J. Serotonin Res. 1997, 4, 159-177.
Cooper, S. J.; Tweed, J.; Raniwalla, J.; Butler, A.; Welch, C. A placebo-controlled comparison of zotepine versus chlropromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr. Scand. 2000, 101, 218-225.
Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45, 789-796.
Meltzer, H. Y.; Okayli, G. Reduction of suicidality during clozapine treatment of neuroleptic resistant schizophrenia: Impact on risk-benefit assessment. Am. J. Psychiatry 1995, 152, 183-190.
Haller, E.; Binder, R. L. Clozapine and seizures. Am. J. Psychiatry 1990, 147, 1069-1071.
Copp, P. J.; Lament, R.; Tennent, T. G. Amitriptyline in clozapine-induced sialorrhea. Br. J. Psychiatry 1991, 159, 166.
Cunningham Owens, D. G. Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 1996, 51, 895-930.
Lieberman, J. A.; Johns, C. A.; Kane, J. M.; Rai, K.; Pisciotta, A. V.; Saltz B. L.; Howard, A. Clozapine-induced agranulocytosis: Non-cross reactivity with other psychotropic drugs. J. Clin. Psychiatry 1988, 49, 271-277.
Grohmann, R.; Schmidt, L. G.; Spieb-Kiefer, C.; Rüther, E. Agranulocytosis and significant leucopenia with neuroleptic drugs: Results from the AMÜP program. Psychopharmacology 1989, 99, S109-S112.
Pisciotta, A. V. Drug induced agranulocytosis peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev. 1990, 4, 226-237.
Bürki, H. R.; Sayer, A. C.; Ruch, W.; Asper, H. Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Structure-activity relationships. Arzneimittelforschung 1977, 27, 1561-1565.
Meltzer, H. Y.; Matsubara, S.; Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
Richelson, E.; Souder, T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci. 2000, 68, 29-39.
Schotte, A.; Janssen, P. F. M.; Gommeren, W.; Luyten, W. H. M. L.; Gompel, P. V.; Lesage, A. S.; De Loore, K.; Leysen, J. E. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996, 124, 57-73.
Chakrabarti, J. K.; Hotten, T. M.; Pullar, I. A.; Steggles, D. J. Synthesis and pharmacological evaluation of CNS activities of [1,2,3]triazolo[4,5-b][1,5]-, imidazolo[4,5-b][1,5]-, and pyrido[2,3-b][1,5]benzodiazepines. 10-Piperazinyl-4H-1,2,3-triazolo[4,5-b]-[1,5]benzodiazepines with neuroleptic activity. J. Med. Chem. 1989, 32, 2375-2381.
Leysen, J. E.; Niemegeers, C. J. E.; Tollenaere, J. P.; Laduron, P. Serotonergic component of neuroleptic receptors. Nature 1978, 272, 168-171.
Waldmeier, P. C.; Delini-Stula, A. A. Serotonin-dopamine interactions in the nigrostriatal system. Eur. J. Pharmacol. 1979, 55, 363-373.
Saller, C. F.; Czupryna, M. J.; Salama, A. I. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. J. Pharmacol. Exp. Ther. 1990, 253, 1162-1170.
Wadenberg, M.-L. G.; Hicks, P. B.; Richter, J. T.; Young, K. A. Enhancement of antipsychotic-like properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907. Biol. Psychiatry 1998, 44, 508-515.
Andersen, K.; Perregaard, J.; Arnt, J.; Nielsen, J. B.; Begtrup, M. Selective, centrally acting serotonin 5-HT2 antagonists. 2. Substituted 3-(4-fluorophenyl)-1H-indoles. J. Med. Chem. 1992, 35, 4823-4831.
Bøgesø, K. P.; Arnt, J.; Hyttel, J.; Pedersen, H. Stereospecific and selective 5-HT2 antagonism in a series of 5-substituted trans-1-piperazino-3-phenylindans. J. Med. Chem. 1993, 36, 2761-2770.
Campiani, G.; Nacci, V.; Bechelli, S.; Ciani, S. M.; Garofalo, A.; Fiorini, I.; Wikström, H.; de Boer, P.; Liao, Y.; Tepper, P. G.; Cagnotto, A.; Mennini, T. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo- [2,1-b][1,3]benzothiazepine structure. J. Med. Chem. 1998, 41, 3763-3772.
Lowe, J. A., III. Atypical antipsychotics based on the D2/5-HT2 ratio hypotheses. Curr. Med. Chem. 1994, 1, 50-60.
Perregaard, J.; Arnt, J.; Bøgesø, K. P.; Hyttel, J.; Sanchez, C. Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles. J. Med. Chem. 1992, 35, 1092-1101.
Meltzer, H. Y. Multireceptor atypical antipsychotic drugs. In Atypical Antipsychotics; Ellenbroek, B. A., Cools, A. R., Eds.; Birrkhaüser Verlag: Basel (CH), 2000; pp 191-213.
Stahl, S. M. Antipsychotic agents. In Essential Psychopharmacology. Neuroscientific Basis and Practical Applications, 2nd Ed.; Cambridge University Press: Cambridge, 2000; pp 401-458.
Van Tol, H. H. M.; Bunzow, J. R.; Guan, H. C.; Sunahara, R. K.; Seeman, P.; Niznik, H. B.; Civelli, O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350, 610-614.
Hrib, N. J. The dopamine D4 receptor: A controversial therapeutic target. Drugs Future 2000, 25, 587-611.
Kebabian, J. W.; Tarazi, F. I.; Kula, N. S.; Baldessarini, R. J. Compounds selective for dopamine receptor subtypes. Drug Discov. Todays 1997, 2, 333-340.
Liégeois, J.-F.; Eyrolles, L.; Bruhwyler, J.; Delarge, J. Dopamine D4 receptors, a new opportunity for research on schizophrenia. Curr. Med. Chem. 1998, 5, 77-100.
Oak, J. N.; Oldenhof, J.; Van Tol, H. H. M. The dopamine D4 receptor: One decade of research. Eur. J. Pharmacol. 2000, 405, 303-327.
Tarazi, F. I.; Baldessarini, R. J. Brain dopamine D4 receptors: Basic and clinical status. Int. J. Neuropsychopharmacol. 1999, 2, 41-58.
Leysen, J. E.; Janssen, P. M. F.; Heylen, L.; Gommeren, W.; Van Gompel, P.; Lesage, A. S., Megens, A. A. H. P.; Schotte, A. Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects. Int. J. Psychiatry Clin. Pract. 1998, 2, S3-S17.
Schmutz, J.; Picard, C. W. Tricyclic neuroleptics: Structure-activity relationships. Handbook Exp. Pharmacol. 1986, 55, 3-25.
Liao, Y.; DeBoer, P.; Meier, E.; Wikström, H. Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: Identification of a novel atypical neuroleptic. J. Med. Chem. 1997, 40, 4146-4153.
Liao, Y.; Venhuis, B. J., Rodenhuis, N.; Timmerman, W.; Wikström, H. New(sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: Chemistry and pharmacological evaluation. J. Med. Chem. 1999, 42, 2235-2244.
Liégeois, J.-F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E.; Mercier, M.; Rogister, F.; Delarge, J. New pyridobenzodiazepine derivatives as potential antipsychotics: Synthesis and neurochemical study. J. Med. Chem. 1993, 36, 2107-2114.
Liégeois, J.-F.; Rogister, F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Inarejos, M. O.; Chleide, E.; Mercier, M.; Delarge, J. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study. J. Med. Chem. 1994, 37, 519-525.
Liégeois, J.-F.; Bruhwyler, J.; Damas, J.; Rogister, F.; Masereel, B.; Géczy, J.; Delarge, J. Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor. Eur. J. Pharmacol. 1995, 273, R1-R3.
Bruhwyler, J.; Liégeois, J.-F.; Chleide, E.; Rogister, F.; Damas, J.; Delarge, J.; Mercier, M. Comparative study of typical neuroleptics, clozapine and new synthesized clozapine-analogues: correlations between neurochemistry and behaviour. Behav. Pharmacol. 1992, 3, 567-579.
Bruhwyler, J.; Chleide, E.; Houbeau, G.; Waegeneer, N.; Mercier, M. Differentiation of haloperidol and clozapine using a complex operant schedule in the dog. Pharmacol. Biochem. Behav. 1993, 44, 181-189.
Bruhwyler, J.; Liégeois, J.-F.; Bergman, J.; Carey, G.; Goudie, A.; Taylor, A.; Meltzer, H. Y.; Delarge, J.; Géczy, J. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties. Pharmacol. Res. 1997, 36, 255-264.
Ellenbroek, B. A.; Liégeois, J.-F.; Bruhwyler, J.; Cools, A. R. The effects of JL 13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J. Pharmacol. Exp. Ther. 2001, 298, 386-391.
Casey, D. E.; Bruhwyler, J.; Delarge, J.; Géczy, J.; Liégeois, J.-F. The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus nonhuman primates. Psychopharmacology 2001, 157, 228-235.
Liégeois, J.-F.; Bruhwyler, J.; Hendrick, J.-C.; Delarge, J.; Legros, J.-J.; Damas, J. Minimal effects of JL 13, a pyridobenzoxazepine derivative with antipsychotic potential, on circulating prolactin levels in male rats. Neurosci. Lett. 2002, 319, 49-52.
Phillips, S. T.; de Paulis, T.; Baron, B. M.; Siegel, B. W.; Seeman, P.; Van Tol, H. H. M.; Guan, H.-C.; Smith, H. E. Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptene analogues of clozapine to dopamine and serotonin receptors. J. Med. Chem. 1994, 37, 2686-2696.
Phillips, S. T.; de Paulis, T.; Neergaard, J. R.; Baron, B. M.; Siegel, B. W.; Seeman, P.; Van Tol, H. H. M.; Guan, H.-C.; Smith, H. E. Binding of 5H-dibenzo[a,d]cycloheptene and dibenz[b,f]-oxepin analogues of clozapine to dopamine and serotonin receptors. J. Med. Chem. 1995, 38, 708-714.
Seeman, P. Antipsychotic drugs, dopamine D2 receptors, and schizophrenia. In Pharmacology and Toxicology Series: Neurotransmitter Receptors in Actions of Antipsychotic Medications; Lidow, M. S., Ed.; CRC Press: New York, 2000; pp 43-63.
Warawa, E. J.; Migler, B. M.; Ohnmacht, C. J.; Needles, A. L.; Gatos, G. C.; McLaren, F. M.; Nelson, C. L.; Kirkland, K. M. Behavioral approach to nondyskinetic dopamine antagonists: Identification of seroquel. J. Med. Chem. 2001, 44, 372-389.
Cooper, S. J.; Butler, A.; Tweed, J.; Welch, C.; Raniwalla, J. Zotepine in the prevention of recurrence: A randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 2000, 150, 237-243.
Steiner, G.; Franke, A.; Hädicke, E.; Lenke, D.; Teschendorf, H.-J.; Hofmann, H.-P.; Kreiskott, H.; Worstmann, W. Tricyclic epines. Novel (E)- and (Z)-11H-dibenz[b, e]azepines as potential central nervous system agents. Variation of the basic side chain. J. Med. Chem. 1986, 29, 1877-1888.
Fryer, R. I.; Earley, J. V.; Field, G. F.; Zally, W.; Sternbach, L. H. A synthesis of amidines from cyclic amides. J. Org. Chem. 1969, 34, 1143-1145.
Jilek, J. O.; Metysova, J.; Nemec, J.; Sedivy, Z.; Pomykacek, J.; Protiva, M. Potential neuroleptics: N-aralkyl, N-(aroylalkyl) and N-pyridyl derivatives of 10-piperazino-10,11-dihydrodibenzo[b,f]-thiepins. Collect. Czech. Chem. Commun. 1975, 40, 3386-3398.
Bürki, H. R.; Fischer, R.; Hunziker, F.; Künzle, F.; Petcher, T. J.; Schmutz, J.; Weber, H. P.; White, T. G. Dibenzo-epines: Effect of the basic side-chain on neuroleptic activity. Eur. J. Med. Chem. 1978, 13, 479-485.
Skoldinov, A. P.; Rayevskii, K. S.; Likhosherstov, A. M.; Stavrovskaja, A. W.; Rüger, C.; Rostock, A.; Röhnert, H. Synthese und neurologische wirkung neuer 11-substituierter 5H- dibenzo [b,e][1,4]diazepine. Pharmazie 1984, 39, 812-813.
Capuano, B.; Crosby, I. T.; Gable, R. W.; Lloyd, E. J. N-Piperonyl analogue of the atypical antipsychotic clozapine. Acta Crystallogr. C 2000, 56, 339-340.
Chakrabarti, J. K.; Horsman, L.; Hotten, T. M.; Pullar, I. A.; Tupper, D. E.; Wright, F. C. 4-Piperazinyl-10H-thieno[2,3-b][1,5]-benzodiazepines as potential neuroleptics. J. Med. Chem. 1980, 23, 878-884.
Bruhwyler, J.; Liégeois, J.-F.; Lejeune, C.; Rogister, F.; Delarge, J.; Géczy, J. New dibenzazepine derivatives with disinhibitory and/or antidepressant potential: Neurochemical and behavioural study in the open-field and forced swimming tests. Behav. Pharmacol. 1995, 6, 830-838.
Liégeois, J.-F.; Scuvée-Moreau, J.; Giesberg, I.; Damas, J.; Bruhwyler, J.; Géczy, J.; Delarge, J.; Dresse, A. Dibenzoazepine analogues: The electrophysiological properties of JL 3, a potential atypical antidepressant. Eur. J. Pharmacol. 1996, 310, 9-12.
Liégeois, J.-F.; Seutin, V.; Scuvée-Moreau, J.; Dresse, A.; Bruhwyler, J.; Géczy, J.; Delarge, J.; Damas, J. Effects of JL 3, a putative antidepressant, on rat noradrenergic and serotonergic systems. Eur. J. Pharmacol. 1999, 386, 211-216.
Hadj Tahar, A.; Bélanger, N.; Bangassoro, E.; Grégoire, L.; Bédard, P. J. Antidyskinetic effect of JL 18, a clozapine analogue, in parkinsonian monkeys. Eur. J. Pharmacol. 2000, 399, 183-186.
Morishita, H.; Katsuragi, T. Existence and pharmacological properties of dopamine D4 receptors in guinea pig vas deferens. Eur. J. Pharmacol. 1999, 374, 255-261.
Nowak, J. Z.; Zawilska, J. B.; Rosiak, J.; Kalaony, T. Melatonin biosynthesis in the retina: Effect of UV-A light. Proc. Eur. Soc. Neurochem. Meet., 11th 1997, 605-609.
Seeman, P.; Corbett, R.; Van Tol, H. H. M. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997, 16, 93-110.
Petcher, T. J.; Weber, H.-P. Conformations of some semirigid neuroleptic drugs. Part 1. Crystal structures of loxapine, clozapine, and HUF-2046 monohydrate {2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine, 8-chloro-11-(4-methylpiperazin-1-yl)dibenzo [b,e][1,4]diazepine, and 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,e][1,4]diazepine monohydrate}. J. Chem. Soc., Perkin Trans. 2 1976, 1415-1420.
Sbit, M.; Dupont, L.; Dideberg, O.; Liégeois, J.-F.; Delarge, J. Structure de la clothiapine. Acta Crystallogr. C 1987, 43, 720-722.
Sbit, M.; Dupont, L.; Dideberg, O.; Liégeois, J.-F.; Delarge, J. Structure du 5-(4-méthylpipérazin-1-yl)pyrido[2,3-b]benzo-1,5- thiazépine. Acta Crystallogr. C 1988, 44, 319-321.
Dupont, L.; Dideberg, O.; Liégeois, J.-F.; Delarge, J. Structure du 10-(4-méthylpipérazin-1-yl)pyrido[4,3-b]benzo-1, 4-thiazépine. Acta Crystallogr. C 1991, 47, 1740-1742.
Ellenbroek, B. A.; Peeters, B. W.; Honig, W.; Cools, A. R. The paw test: A behavioral pardigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 1987, 93, 343-348.
Ellenbroek, B. A.; Lubbers, L. J.; Cools, A. R. Activity of seroquel (ICI 204,636) in animal models for atypical properties of antipsychotics - A comparison with clozapine. Neuropsychopharmacology 1996, 15, 406-416.
Porsolt, R. D.; Bertin, A.; Jalfre, M. Behavioral despair in mice: A primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229, 327-336.
Stockmeier, C. A.; DiCarlo, J. J.; Zhang, Y.; Thompson, P.; Meltzer, H. Y. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J. Pharmacol. Exp. Ther. 1993, 266, 1374-1384.
Wadenberg, M.-L. G.; Sills, T. L.; Fletcher, P. J.; Kapur, S. Antipsychotic-like effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats. Biol. Psychiatry 2000, 47, 670-676.
Kapur, J.; Cho, R.; Jones, C.; McKay, G.; Zipursky, R. B. Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biol. Psychiatry 1999, 45, 1217-1220.
Brookes, P.; Terry, R. J.; Walker, J. The chemotherapy of filariasis. Analogues of diethylcarbamazine (1-diethylcarbamoyl-4-methylpiperazine) derived from 2:4′ and 4:4′-dipiperidyl, homopiperazine, and 4-aminopiperidine. J. Chem. Soc. 1957, 3165-3172.
Dostert, P.; Imbert, T.; Langlois, M.; Bucher, B.; Mocquet, G. Studies on the neuroleptic benzamides. III. Synthesis and antidopaminergic properties of new 3-nortropane derivatives. Eur. J. Med. Chem. 1984, 19, 105-110.
Leysen, J. E.; Niemegeers, C. J. E.; Van Nueten, J. M.; Laduron, P. [3H]Ketanserin (R41468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 1982, 21, 301-314.
Skarsfeldt, T.; Hyttel, J. The St 587-induced flexor reflex in pithed rats: A model to evaluate central α1-receptor blocking properties. Eur. J. Pharmacol. 1986, 125, 333-340.
Cheng, Y.-C.; Prusoff, W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
